Try our mobile app

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Published: 2023-03-18 14:00:00 ET
<<<  go to SNY company page

Dupixent®(dupilumab) late-breaking dataat AAD show significant improvements in signs and symptomsofmoderate-to-severe atopic hand and foot dermatitis

  • More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
  • Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week

Paris and Tarrytown, N.Y.March18, 2023. Positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented today. The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

Eric L. Simpson, M.D.Frances J. Storrs Professor of Medical Dermatology at the Oregon Health and Science University and principal investigator of this trial“Atopic hand and foot dermatitis can extensively disrupt the lives of patients, given the intense itch and painful skin lesions it causes on essential bodyareas. In this trial, Dupixent significantly improved disease signs, symptoms and quality of life measures for this particularly difficult-to-treat subset of atopic dermatitis patients, with itch improvement seen as early as one week after the first dose. While the efficacy and safety profile of Dupixent is well-established for atopic dermatitis more broadly, these positive results are the first demonstrating the impact on specific and heavily usedareas of the body.”

In the trial, patients received Dupixent (n=67) every two weeks (adults 300 mg, adolescents 200 mg or 300 mg based on body weight) or placebo (n=66). At 16 weeks, patients treated with Dupixent experienced the following:

  • 40% achieved clear or almost clear skin on hands and feet compared to 17% with placebo (p≤0.01), the primary endpoint.
  • 52% saw a clinically meaningful reduction in itch on hands and feet compared to 14% with placebo (p